In this study, we tested the anti-leukemia activities of CD19 BiTE (blinatumomab) RNA-electroporated T cells that were generated through CD3/CD28 Dynal Bead stimulation or a rapid T-cell expansion protocol (REP) and found that the REP T cells transferred with a CD19 BiTE nearly completely eradicated the leukemia cells in the mice and resulted in sustained survival. Here, CD28 is linked to leukemia.